202 related articles for article (PubMed ID: 36481527)
1. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
Vatankhah F; Salimi N; Khalaji A; Baradaran B
Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
4. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
[TBL] [Abstract][Full Text] [Related]
8. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract][Full Text] [Related]
9. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J; Lv X; Zhang Z; Huang Z; Zhang E
Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
[TBL] [Abstract][Full Text] [Related]
10. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
Gadaleta-Caldarola G; Rizzo A; Dadduzio V; Lombardi L; Gadaleta-Caldarola A; Infusino S; Cusmai A; Citrigno C; Palmiotti G
Curr Oncol; 2022 Oct; 29(10):7925-7931. PubMed ID: 36290903
[TBL] [Abstract][Full Text] [Related]
11. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
12. Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells.
Waenphimai O; Mahalapbutr P; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
Eur J Pharmacol; 2022 May; 922():174899. PubMed ID: 35337815
[TBL] [Abstract][Full Text] [Related]
13. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in cholangiocarcinoma.
Beri N
Immunotherapy; 2023 May; 15(7):541-551. PubMed ID: 37096964
[TBL] [Abstract][Full Text] [Related]
15. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
[TBL] [Abstract][Full Text] [Related]
16. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
17. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
19. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
20. Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma.
Fu J; McGrath NA; Lee J; Wang X; Brar G; Xie C
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):485-492. PubMed ID: 35307294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]